From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go. But researchers still face a fundamental challenge: getting those therapies to the organs where they are needed most while limiting side effects elsewhere in the body.
Now, researchers at Georgia Tech and Emory University have discovered that delivering LNP medicines directly to various areas of the gastrointestinal (GI) tract — from the cheeks to the stomach to the rectum — could alter where the therapies travel in the body after being absorbed. This enables more precise targeting and opens new possibilities for mRNA therapies and vaccines.
Several technologies are currently in development that enable oral and GI nucleic acid delivery, including pills, patches, and endoscopic injections.
"Here we show that oral delivery of mRNA wouldn’t just enhance the patient experience compared to injections, but it also may enable improved or even completely new treatments," said Alex Abramson, an assistant professor in the School of Chemical and Biomolecular Engineering (ChBE).
"We're able to deliver to organs that are hard to target via traditional administration methods while simultaneously reducing uptake in organs normally associated with toxicity."
The researchers published their findings in ACS Nano in September.